Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Spinomix Announces a Milestone Payment from Debiopharm

Published: Thursday, January 09, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Appointment of Nasri Nahas as Company’s new CEO.

Spinomix SA and Debiopharm Group™ have announced the successful achievement of a second development milestone on Spinomix’ two proprietary technologies, namely MagPhase™ and FibroTrap™.

In conjunction with the terms of the investment agreement, Spinomix is to receive an undisclosed second tranche payment from Debiopharm.

In January 2013, Spinomix closed its series A $ 3 million equity investment in a round led by Debiopharm. Since then, Spinomix has built a series of MagPhase™ pilot instruments for field-testing for purification of nucleic acids.

Four instruments were installed with academic and industry partners to initiate the field testing program. MagPhase™ is an automated sample preparation platform based on magnetic nanoparticles and microfluidic disposable cartridges offering cost-efficient and high quality DNA extraction.

Spinomix also successfully demonstrated the FibroTrap™ tube prototype assay in key applications laid out in the development plan. FibroTrap™ is a fibrinogen-based technology, enabling highly specific and sensitive isolation of targeted cells and molecules in clinical samples directly in routine collection tubes, thus simplifying enormously the workflow.

“This second milestone is an important achievement and marks the successful completion of a key step towards the establishment of new standards of improved workflow for diagnostic testing” said Heiner Dreisman, Chairman of the board of directors of Spinomix. “We are also very happy on the same occasion to announce that we have secured Nasri Nahas as our new CEO. Nasri’s broad experience of biotech startups management and business development makes him an ideal candidate to lead the next stage of Spinomix’ development.”

Nasri Nahas brings 20 years of experience in the biotech start-ups industry, from both the research and business perspectives. Over the course of his 12 years tenure as the CEO of Geneva Bioinformatics (GeneBio) SA, he lead GeneBio’s operations and successfully built an exceptional and highly motivated team of industry experts who grew the company from a start-up-like setting to an experienced, well-established and renowned organization. As CEO he personally oversaw the business development activities and expanded the company’s strategic network to encompass a wide palette of major industry players.

“Spinomix enjoys two amazing technologies in the growing diagnostics market and benefits from a unique team of industry experts backed by the instrumental support of our partnership with Debiopharm” said Nasri Nahas. “This makes Spinomix rightly suited to face the challenges that are ahead of us. I am very proud and thrilled to lead our next stages”.

“Our partnership with Spinomix has been very productive and the advancement of their diagnostic tools is a witness to their determination and professionalism. We are confident that the company will rapidly further develop these diagnostic sample treatment products for the delivery of faster, lower cost and more accurate results” added Thierry Mauvernay, Delegate of the Board of Debiopharm Group. “I am very pleased about Nasri Nahas joining the Spinomix’ team. He has significant experience in strategic management and we feel he is highly qualified to lead the company through the next stages of its development strategy”.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos